Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RXC004 (Zamaporvint) Monotherapy and Combination with Pembrolizumab in Advanced Solid Tumours
NCT04907851Phase 2Completed
- Sponsor
- Redx Pharma
- Start
- Dec 2021
- Primary completion
- Nov 2023
- Modality
- Orthosteric Ligands
- Countries
- 2
01
Overview
Phase 2, open-label trial of zamaporvint in pancreatic ductal adenocarcinoma (PDAC) and biliary tract cancer (BTC) (3 arms), sponsored by Redx Pharma. Primary endpoints: Progression Free Survival Rate at 6 Months and Objective Response Rate up to 23 months. Started Dec 2021; status: completed.
02
Drugs
zamaporvint
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)biliary tract cancer (BTC)
Beyond the preview
Go deeper on NCT04907851.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04907851.